Skip to main content

Powering the Immune System to Transform Lives

Newsroom

Discover the stories behind our science, people and communities.

Stories

Ira Jacobson story

Insights From Dr. Tatyana Kushner on New CHD Recommendations

Gregg's story

I Thought I Was Healthy as an Ox. Then My Doctor Called at 7:30 A.M.

Timeline thumbnail

10 Years of Vir Biotechnology: Milestones That Shaped the Journey

All Stories

Press Releases

November 8, 2026

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

November 8, 2026

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

November 5, 2026

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call

All Press Releases

In the News

FIERCE BIOTECH – Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs

ENDPOINTS – Vir makes solid tumor T cell engager deal with Gilead

AJMC – Tobevibart Combo Shows High Hepatitis D Efficacy: Tarik Asselah, MD, PhD

All NewS Content

Social Media

Stay connected. Follow us on LinkedIn and X.

Media Resources

Vir Biotechnology brand logo and colors

Media Contact

Caren Scannell
cscannell@vir.bio